Bristol Myers’ top autoimmune drug prospect takes a hit in mid-stage trial
Deucravacitinib is important to Bristol Myers for several reasons.
The drug is seen as a potential top-seller, leading a new class of oral drugs that could challenge...
Continue Reading →
